Why the study?
Does acetylator phenotype affect the plasma NAPA/procainamide ratio in patients taking procainamide?
Population
14 people of known acetylator phenotype taking procainamide for more than 3 days.
Comparison
Procainamide therapy for more than 3 days vs Fast acetylator phenotype versus slow acetylator…
Design
Cross-sectional
Authors
Loading...
Acetylator phenotype affects procainamide metabolite ratios; hypothesis-generating for personalized dosing, pending outcome trials.
Does acetylator phenotype affect the plasma NAPA/procainamide ratio in patients taking procainamide?
Procainamide is acetylated by polymorphic N-acetyltransferase, resulting in significantly higher active metabolite (NAPA) levels in fast acetylators, which likely contributes to the drug's antiarrhythmic efficacy.
Reidenberg et al. (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: